Gelteq Limited (NASDAQ:GELS) Short Interest Update

Gelteq Limited (NASDAQ:GELS) was the target of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 112,420 shares, a decrease of 32.9% from the June 30th total of 167,463 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average daily volume of 41,384 shares, the days-to-cover ratio is presently 2.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Gelteq

An institutional investor recently bought a new position in Gelteq stock. Susquehanna International Group LLP purchased a new stake in Gelteq Limited (NASDAQ:GELS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq as of its most recent filing with the SEC.

Gelteq Stock Down 5.6%

NASDAQ GELS opened at $0.52 on Friday. Gelteq has a 1-year low of $0.39 and a 1-year high of $2.02. The firm’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.71.

Gelteq (NASDAQ:GELS) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.12) earnings per share (EPS) for the quarter.

About Gelteq

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.